Dopamine-derived biological reactive intermediates and protein modifications: Implications for Parkinson's disease

Chemico-Biological Interactions

Volumn 192, Issue 1-2, 2011, Pages 118-121

  Jinsmaa, Yunden ^a   Florang, Virginia R ^a   Rees, Jennifer N ^a   Mexas, Lydia M ^a   Eckert, Laurie L ^a   Allen, Erin M G ^a   Anderson, David G ^a   Doorn, Jonathan A ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

3,4 Dihydroxyphenylacetaldehyde; Biological reactive intermediate; Dopamine; Parkinson's disease; Protein modification

Indexed keywords

3,4 DIHYDROXYPHENYLACETALDEHYDE; DOPAMINE; UNCLASSIFIED DRUG;

BIOTRANSFORMATION; CELL LINE; CHEMICAL STRUCTURE; CONFERENCE PAPER; CONTROLLED STUDY; DOPAMINE METABOLISM; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN ANALYSIS; PROTEIN CROSS LINKING; PROTEIN MODIFICATION; PROTEIN SYNTHESIS;

ANIMALS; CELL LINE; DOPAMINE; PARKINSON DISEASE; PROTEINS;

EID: 79958035799     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2011.01.006     Document Type: Conference Paper

References (32)

1. P. Jenner Oxidative stress in Parkinson's disease Ann. Neurol. 53 Suppl. 3 2003 S26 S36 (discussion S36-28)
2. D.A. Drechsel, and M. Patel Role of reactive oxygen species in the neurotoxicity of environmental agents implicated in Parkinson's disease Free Radic. Biol. Med. 44 11 2008 1873 1886
3. P.J. Landrigan, B. Sonawane, R.N. Butler, L. Trasande, R. Callan, and D. Droller Early environmental origins of neurodegenerative disease in later life Environ. Health Perspect. 113 9 2005 1230 1233 (Pubitemid 41387665)
4. W.J. Burke, S.W. Li, E.A. Williams, R. Nonneman, and D.S. Zahm 3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis Brain Res. 989 2 2003 205 213 (Pubitemid 37211424)
5. W.J. Burke 3,4-Dihydroxyphenylacetaldehyde: a potential target for neuroprotective therapy in Parkinson's disease Curr. Drug Targets CNS Neurol. Disord. 2 2 2003 143 148
6. D.G. Graham Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones Mol. Pharmacol. 14 4 1978 633 643 (Pubitemid 8402469)
7. T.G. Hastings, and M.J. Zigmond Identification of catechol-protein conjugates in neostriatal slices incubated with [3H]dopamine: impact of ascorbic acid and glutathione J. Neurochem. 63 3 1994 1126 1132 (Pubitemid 24266628)
8. M.B. Mattammal, R. Strong, V.M. Lakshmi, H.D. Chung, and A.H. Stephenson Prostaglandin H synthetase-mediated metabolism of dopamine: implication for Parkinson's disease J. Neurochem. 64 4 1995 1645 1654
9. G. Eisenhofer, I.J. Kopin, and D.S. Goldstein Catecholamine metabolism: a contemporary view with implications for physiology and medicine Pharmacol. Rev. 56 3 2004 331 349 (Pubitemid 39096594)
10. S.A. Marchitti, R.A. Deitrich, and V. Vasiliou Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase Pharmacol. Rev. 59 2 2007 125 150 (Pubitemid 46855437)
11. W.J. Burke, S.W. Li, H.D. Chung, D.A. Ruggiero, B.S. Kristal, E.M. Johnson, P. Lampe, V.B. Kumar, M. Franko, E.A. Williams, and D.S. Zahm Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases Neurotoxicology 25 1-2 2004 101 115 (Pubitemid 38044173)
12. G.E. Nilsson, and O. Tottmar Biogenic aldehydes in brain: on their preparation and reactions with rat brain tissue J. Neurochem. 48 5 1987 1566 1572 (Pubitemid 17068744)
13. M.J. LaVoie, B.L. Ostaszewski, A. Weihofen, M.G. Schlossmacher, and D.J. Selkoe Dopamine covalently modifies and functionally inactivates parkin Nat. Med. 11 11 2005 1214 1221 (Pubitemid 43093669)
14. F. Ungar, B. Tabakoff, and S.G. Alivisatos Inhibition of binding of aldehydes of biogenic amines in tissues Biochem. Pharmacol. 22 15 1973 1905 1913
15. A.G. Kanthasamy, M. Kitazawa, A. Kanthasamy, and V. Anantharam Dieldrin-induced neurotoxicity: relevance to Parkinson's disease pathogenesis Neurotoxicology 26 4 2005 701 719 (Pubitemid 41175903)
16. Y. Jinsmaa, V.R. Florang, J.N. Rees, D.G. Anderson, S. Strack, and J.A. Doorn Products of oxidative stress inhibit aldehyde oxidation and reduction pathways in dopamine catabolism yielding elevated levels of a reactive intermediate Chem. Res. Toxicol. 22 5 2009 835 841
17. T.J. Shafer, and W.D. Atchison Transmitter, ion channel and receptor properties of pheochromocytoma (PC12) cells: a model for neurotoxicological studies Neurotoxicology 12 3 1991 473 492
18. Y. Hirata, K. Adachi, and K. Kiuchi Activation of JNK pathway and induction of apoptosis by manganese in PC12 cells J. Neurochem. 71 4 1998 1607 1615 (Pubitemid 28443033)
19. M. Kitazawa, V. Anantharam, and A.G. Kanthasamy Dieldrin-induced oxidative stress and neurochemical changes contribute to apoptopic cell death in dopaminergic cells Free Radic. Biol. Med. 31 11 2001 1473 1485 (Pubitemid 33145318)
20. V.R. Florang, J.N. Rees, N.K. Brogden, D.G. Anderson, T.D. Hurley, and J.A. Doorn Inhibition of the oxidative metabolism of 3,4- dihydroxyphenylacetaldehyde, a reactive intermediate of dopamine metabolism, by 4-hydroxy-2-nonenal Neurotoxicology 28 1 2007 76 82 (Pubitemid 46187263)
21. J.N. Rees, V.R. Florang, L.L. Eckert, and J.A. Doorn Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol Chem. Res. Toxicol. 22 7 2009 1256 1263
22. D.T. Dexter, C.J. Carter, F.R. Wells, F. Javoy-Agid, Y. Agid, A. Lees, P. Jenner, and C.D. Marsden Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease J. Neurochem. 52 2 1989 381 389 (Pubitemid 19037600)
23. H. Esterbauer, R.J. Schaur, and H. Zollner Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes Free Radic. Biol. Med. 11 1 1991 81 128 (Pubitemid 121003917)
24. A. Yoritaka, N. Hattori, K. Uchida, M. Tanaka, E.R. Stadtman, and Y. Mizuno Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease Proc. Natl. Acad. Sci. U.S.A. 93 7 1996 2696 2701 (Pubitemid 26114311)
25. D.Y. Mitchell, and D.R. Petersen Inhibition of rat hepatic mitochondrial aldehyde dehydrogenase-mediated acetaldehyde oxidation by trans-4-hydroxy-2- nonenal Hepatology 13 4 1991 728 734
26. J.J. Hjelle, J.H. Grubbs, and D.R. Petersen Inhibition of mitochondrial aldehyde dehydrogenase by malondialdehyde Toxicol. Lett. 14 1-2 1982 35 43 (Pubitemid 13255365)
27. J.N. Rees, V.R. Florang, D.G. Anderson, and J.A. Doorn Lipid peroxidation products inhibit dopamine catabolism yielding aberrant levels of a reactive intermediate Chem. Res. Toxicol. 20 10 2007 1536 1542 (Pubitemid 350057224)
28. I. Lamensdorf, G. Eisenhofer, J. Harvey-White, Y. Hayakawa, K. Kirk, and I.J. Kopin Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4-dihydroxyphenylacetaldehyde J. Neurosci. Res. 60 4 2000 552 558 (Pubitemid 30252918)
29. J. Segura-Aguilar, S. Baez, M. Widersten, C.J. Welch, and B. Mannervik Human class Mu glutathione transferases, in particular isoenzyme M2-2, catalyze detoxication of the dopamine metabolite aminochrome J. Biol. Chem. 272 9 1997 5727 5731 (Pubitemid 27102401)
30. S. Baez, J. Segura-Aguilar, M. Widersten, A.S. Johansson, and B. Mannervik Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes Biochem. J. 324 Pt 1 1997 25 28 (Pubitemid 27229361)
31. W.M. Panneton, V.B. Kumar, Q. Gan, W.J. Burke, J.E. Galvin, The neurotoxicity of DOPAL: behavioral and stereological evidence for its role in Parkinson disease pathogenesis, PLoS One 5(12) e15251 (2010).
32. D.S. Goldstein, P. Sullivan, C. Holmes, I.J. Kopin, M.J. Basile, D.C. Mash, Catechols in post-mortem brain of patients with Parkinson disease, Eur. J. Neurol. (2010).